Vera Therapeutics, Inc. - COMMON STOCK (VERA)

Historical Holders from Q2 2021 to Q3 2025

Symbol
VERA on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
64,326,281
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
65,065,875
Holdings value
$1,890,711,857
% of all portfolios
0.01%
Number of holders
172
Number of buys
98
Number of sells
-80
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vera Therapeutics, Inc. - COMMON STOCK (VERA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 8.9% $134,640,000 5,610,000 Avoro Capital Advisors LLC 31 Dec 2024
PRICE T ROWE ASSOCIATES INC /MD/ 5.7% $106,551,338 3,666,598 T. Rowe Price Associates, Inc. 30 Sep 2025
Kynam Capital Management, LP 5.37% $83,444,698 3,426,887 Kynam Capital Management, LP 30 Jun 2025
Flynn James E 5.25% $75,299,151 3,348,117 Deerfield Mgmt, L.P. 06 Jun 2025

Institutional Holders of Vera Therapeutics, Inc. - COMMON STOCK (VERA)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 65,065,875 $1,890,711,857 +$37,075,375 $29.06 172
2025 Q2 63,893,006 $1,505,324,602 +$17,298,219 $23.56 171
2025 Q1 62,915,975 $1,512,522,250 -$90,036,678 $24.02 176
2024 Q4 62,912,622 $2,660,465,176 +$389,856,746 $42.29 177
2024 Q3 53,519,938 $2,365,061,400 -$1,769,076 $44.20 172
2024 Q2 52,988,211 $1,917,110,562 +$57,678,654 $36.18 169
2024 Q1 51,298,718 $2,212,007,022 +$474,171,827 $43.12 157
2023 Q4 41,345,437 $635,880,813 +$44,778,975 $15.38 93
2023 Q3 39,258,779 $538,195,352 +$9,620,413 $13.71 84
2023 Q2 38,127,621 $611,912,465 +$42,587,635 $16.05 76
2023 Q1 37,354,429 $289,749,836 +$137,641,985 $7.76 69
2022 Q4 21,331,464 $412,748,829 -$7,253,468 $19.35 57
2022 Q3 21,539,667 $459,015,997 +$19,117,341 $21.31 55
2022 Q2 20,391,008 $277,615,038 +$7,846,841 $13.61 49
2022 Q1 19,483,745 $457,319,068 +$130,146,246 $23.49 49
2021 Q4 14,054,730 $374,899,000 +$10,499,638 $26.72 37
2021 Q3 14,710,587 $252,433,000 +$4,174,540 $17.35 30
2021 Q2 14,513,290 $186,104,000 +$186,104,000 $13.25 21